ASRT Stock Recent News

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Matthew Kreps - IR Brendan O'Grady - CEO Ajay Patel - CFO Conference Call Participants James Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets, LLC Naz Rahman - Maxim Group Scott Henry - AGP Operator Thank you for standing by. My name is Eric, and I'll be your conference operator today.

Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024.

LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who acquired Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio” or the “Company”) common stock issued in exchange for Spectrum Pharmaceuticals, Inc. (“Spectrum”) common stock in connection with Assertio's July 31, 2023 merger with Spectrum (the “Merger”), charging the Company and certain of its current and former senior executives and directors with violations of the federal securities laws (collectively, “Defendants”).

LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective December 23, 2024, the Compensation Committee of the Company's Board of Directors granted Mary Pietryga, the Company's newly-hired Senior Vice President, Chief Commercial Officer, 62,500 restricted stock units (“RSUs”) and 275,000 stock options (“options”).

LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective October 1, 2024, the Compensation Committee of the Company's Board of Directors granted two newly-hired employees a total of 16,325 restricted stock units (“RSUs”) and 24,670 stock options (“options”).

LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will host investor meetings at two investor conferences taking place in New York City during September 10-12, 2024.

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - Chief Executive Officer Ajay Patel - Senior Vice President and Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Raghuram Selvaraju - H.C. Wainwright Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners James Sidoti - Sidoti and Company Operator Thank you for standing by.

Assertio (ASRT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.13 per share a year ago.

Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4 Million LAKE FOREST, Ill., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the second quarter ended June 30, 2024.